MA52595A - Formulation liquide stable de gonadotrophines - Google Patents

Formulation liquide stable de gonadotrophines

Info

Publication number
MA52595A
MA52595A MA052595A MA52595A MA52595A MA 52595 A MA52595 A MA 52595A MA 052595 A MA052595 A MA 052595A MA 52595 A MA52595 A MA 52595A MA 52595 A MA52595 A MA 52595A
Authority
MA
Morocco
Prior art keywords
gonadotrophins
liquid formulation
stable liquid
stable
formulation
Prior art date
Application number
MA052595A
Other languages
English (en)
Other versions
MA52595B1 (fr
Inventor
Charlotte Højer-Pedersen
Helen Ulrika Sjögren
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52595(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA52595A publication Critical patent/MA52595A/fr
Publication of MA52595B1 publication Critical patent/MA52595B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA52595A 2016-02-24 2017-02-24 Formulation liquide stable de gonadotrophines MA52595B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603280.7A GB201603280D0 (en) 2016-02-24 2016-02-24 Stable liquid gonadotropin formulation
PCT/EP2017/054325 WO2017144659A1 (fr) 2016-02-24 2017-02-24 Formulation liquide stable de gonadotrophines

Publications (2)

Publication Number Publication Date
MA52595A true MA52595A (fr) 2021-03-17
MA52595B1 MA52595B1 (fr) 2023-12-29

Family

ID=55806922

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43686A MA43686B1 (fr) 2016-02-24 2017-02-24 Formulation liquide stable de gonadotrophines
MA52595A MA52595B1 (fr) 2016-02-24 2017-02-24 Formulation liquide stable de gonadotrophines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA43686A MA43686B1 (fr) 2016-02-24 2017-02-24 Formulation liquide stable de gonadotrophines

Country Status (36)

Country Link
US (3) US10792334B2 (fr)
EP (3) EP3791860B1 (fr)
JP (3) JP6932710B2 (fr)
KR (1) KR20180114178A (fr)
CN (2) CN113398250B (fr)
AR (1) AR107782A1 (fr)
AU (2) AU2017222292B2 (fr)
BR (1) BR112018015166A2 (fr)
CA (1) CA3012759A1 (fr)
CL (1) CL2018001984A1 (fr)
CO (1) CO2018007810A2 (fr)
DK (2) DK3419595T3 (fr)
EA (1) EA036383B1 (fr)
ES (2) ES2966262T3 (fr)
FI (1) FI3791860T3 (fr)
GB (1) GB201603280D0 (fr)
HR (2) HRP20231477T1 (fr)
HU (2) HUE064432T2 (fr)
IL (1) IL260626B2 (fr)
JO (1) JOP20170046B1 (fr)
LT (2) LT3791860T (fr)
MA (2) MA43686B1 (fr)
MD (2) MD3791860T2 (fr)
MX (1) MX2018010201A (fr)
MY (1) MY193138A (fr)
PH (1) PH12018501688A1 (fr)
PL (2) PL3791860T3 (fr)
PT (2) PT3791860T (fr)
RS (2) RS64929B1 (fr)
SG (1) SG11201806140SA (fr)
SI (2) SI3791860T1 (fr)
TN (1) TN2018000284A1 (fr)
TW (1) TWI755377B (fr)
UA (1) UA123107C2 (fr)
WO (1) WO2017144659A1 (fr)
ZA (1) ZA201804944B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
US20190262314A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
JP2022504427A (ja) * 2018-10-02 2022-01-13 インノコア テクノロジーズ ホールディング ビー．ブイ． ヒト絨毛性ゴナドトロピン（ｈＣＧ）の徐放配合物
CN114404575A (zh) * 2020-12-07 2022-04-29 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
WO2022197963A1 (fr) * 2021-03-19 2022-09-22 Pfizer Inc. Compositions d'hormone de croissance à action prolongée

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0803832A3 (fr) 1996-02-28 2000-05-31 Hitachi, Ltd. Dispositif d'affichage de solde du type étui à carte
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
WO2000004913A1 (fr) * 1998-07-23 2000-02-03 Eli Lilly And Company Formulations de fsh et de variants de fsh, produits et procedes
AU2006259664A1 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
ES2393233T3 (es) * 2007-11-01 2012-12-19 Merck Serono S.A. Formulaciones de LH líquidas
KR20190045414A (ko) 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009098318A1 (fr) 2008-02-08 2009-08-13 Biogenerix Ag Formulation liquide de fsh
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
WO2011108010A2 (fr) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited Préparation liquide thermostable de gonadotropines
EP2417982A1 (fr) * 2010-07-30 2012-02-15 Ferring B.V. Stabilisation de gonadotrophines
NZ718960A (en) * 2013-11-12 2017-06-30 Cadila Healthcare Ltd Formulation for gonadotropins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Also Published As

Publication number Publication date
AU2022200027A1 (en) 2022-02-03
PH12018501688A1 (en) 2019-05-27
JP2021191760A (ja) 2021-12-16
AR107782A1 (es) 2018-06-06
PL3419595T3 (pl) 2021-06-14
CN108883061B (zh) 2021-06-08
ES2966262T3 (es) 2024-04-19
LT3791860T (lt) 2023-12-11
RS64929B1 (sr) 2023-12-29
IL260626B2 (en) 2023-08-01
EA036383B1 (ru) 2020-11-03
JP2023164573A (ja) 2023-11-10
CL2018001984A1 (es) 2018-09-14
HRP20210367T1 (hr) 2021-04-16
SG11201806140SA (en) 2018-08-30
HRP20231477T1 (hr) 2024-03-01
CN108883061A (zh) 2018-11-23
JOP20170046B1 (ar) 2021-08-17
US20230372447A1 (en) 2023-11-23
MA43686A (fr) 2019-01-02
MD3419595T2 (ro) 2021-06-30
FI3791860T3 (fi) 2024-01-11
HUE053492T2 (hu) 2021-06-28
PT3419595T (pt) 2021-03-29
BR112018015166A2 (pt) 2018-12-18
ZA201804944B (en) 2023-02-22
JP2019507153A (ja) 2019-03-14
EP3791860B1 (fr) 2023-10-11
DK3791860T3 (da) 2023-12-18
CO2018007810A2 (es) 2018-10-22
AU2017222292A1 (en) 2018-07-26
US11666635B2 (en) 2023-06-06
CN113398250B (zh) 2024-02-23
LT3419595T (lt) 2021-03-10
TN2018000284A1 (en) 2020-01-16
TWI755377B (zh) 2022-02-21
US10792334B2 (en) 2020-10-06
CA3012759A1 (fr) 2017-08-31
PL3791860T3 (pl) 2024-03-18
GB201603280D0 (en) 2016-04-13
EA201891905A1 (ru) 2019-02-28
EP4257149A2 (fr) 2023-10-11
CN113398250A (zh) 2021-09-17
HUE064432T2 (hu) 2024-03-28
EP3791860A1 (fr) 2021-03-17
KR20180114178A (ko) 2018-10-17
SI3419595T1 (sl) 2021-04-30
UA123107C2 (uk) 2021-02-17
RS61604B1 (sr) 2021-04-29
US20210236600A1 (en) 2021-08-05
EP3419595B1 (fr) 2021-01-06
TW201733612A (zh) 2017-10-01
MD3791860T2 (ro) 2024-03-31
IL260626A (fr) 2018-09-20
AU2017222292B2 (en) 2021-12-16
MA43686B1 (fr) 2021-03-31
ES2862193T3 (es) 2021-10-07
MA52595B1 (fr) 2023-12-29
MX2018010201A (es) 2019-06-06
SI3791860T1 (sl) 2024-01-31
EP3419595A1 (fr) 2019-01-02
PT3791860T (pt) 2023-12-15
WO2017144659A1 (fr) 2017-08-31
EP4257149A3 (fr) 2023-12-20
JP6932710B2 (ja) 2021-09-08
US20190060409A1 (en) 2019-02-28
IL260626B1 (en) 2023-04-01
DK3419595T3 (da) 2021-03-29
MY193138A (en) 2022-09-26

Similar Documents

Publication Publication Date Title
DK3479819T3 (da) Stabilt væskeformigt farmaceutisk præparat
DK3639813T3 (da) Flydende formulering omfattende nikotin til aerosolindgivelse
MA46334A (fr) Composition pharmaceutique liquide
DK3532029T3 (da) Flydende farmaceutisk sammensætning
MA52595A (fr) Formulation liquide stable de gonadotrophines
HK1222557A1 (zh) 的穩定的液體製劑
CL2016001313A1 (es) Formulaciones listas de fertilizante líquido de bifentrina.
MA45995A (fr) Pulvérisation de naloxone liquide
DK3544584T3 (da) Farmaceutisk parenteral formulering indeholdende cargluminsyre
FR3039396B1 (fr) Base de formulation cosmetique concentree
GB2548424B (en) Liquid pharmaceutical composition of clonidine
GB201718468D0 (en) Stable liquid pharmaceutical compositions of bortezomb
MA43166A (fr) Formulation de fviii
GB201720793D0 (en) Stable liquid formulations of pemetrexed
DK3324736T3 (da) Hidtil ukendt spot-on-aktivstofformulering
CL2016002554S1 (es) Ampolleta
FR3019804B1 (fr) Flacon de conditionnement de liquide
ITUA20161319A1 (it) Dispositivo diffusore di sostanze liquide
TH1601002253A (th) สูตรผสมของอินซูลินกลูไลซีนที่คงตัว